| Cases (n = 49) | Controls B (n = 49) | p value |
---|---|---|---|
Gender | Â | Â | 0.83 |
Male | 32 (65.3%) | 31 (63.3%) | Â |
Female | 17 (34.7%) | 18 (36.7%) | Â |
Intensive care unit (ICU) | Â | Â | 0.61 |
Medical ICU | 26 (53.1%) | 22 (47.8%) | Â |
Surgical ICU | 23 (46.9%) | 24 (52.2%) | Â |
Admission to the ICU | Â | Â | 0.54 |
Direct admission | 27 (55.1%) | 24 (48.9%) | Â |
Transfer from the ward | 22 (44.9%) | 25 (51.1%) | Â |
Diabetes | 15 (30.6%) | 13 (26.5%) | 0.66 |
Renal impairment | 9 (18.4%) | 13 (26.5%) | 0.33 |
Cerebrovascular accident | 5 (10.2%) | 12 (24.5%) | 0.11 |
Peptic ulcer disease | 3 (6.1%) | 1 (2.1%) | 0.62 |
Myocardial infarction | 8 (16.3%) | 9 (18.4%) | 0.79 |
Congestive cardiac failure | 3 (6.1%) | 0 (0%) | 0.24 |
Liver disease | 2 (4.1%) | 1 (2.1%) | 1 |
Malignancy | 4 (8.2%) | 0 (0%) | 0.12 |
Central venous catheter | 45 (91.8%) | 45 (91.8%) | 1 |
Endotracheal intubation | 49 (100%) | 47 (95.9%) | 0.49 |
Mean days of duration of mechanical ventilation (SD) | 7.9 (SD6.8) | 7.6 (SD2.9) | 0.80 |
Prior SGNB** infection or colonization in the past 6Â months | 3 (6.1%) | 0 (0%) | 0.24 |
Prior Carbapenems in the past 6Â months | 23 (46.9%) | 23 (46.9%) | 1 |
Prior 3rd generation Cephalosporins in the past 6Â months | 25 (51.1%) | 15 (30.6%) | 0.05 |
Surgery prior to RGNB*** infection | 23 (46.9%) | 27 (55.1%) | 0.42 |
Stay in ICU for more than 5Â days | 38 (77.6%) | 37 (75.5%) | 0.81 |
Mortality | 28 (57.1%) | 15 (30.6%) | 0.008 |
Mean age (SD) | 59.5 (SD18.2) | 57.1 (SD16.4) | 0.5 |
Mean APACHEII (SD) | 20.4 (SD7.2) | 20.6 (SD5.8) | 0.88 |
Mean age adjusted Charlson score (SD) | 3.5 (SD3.1) | 3.2 (SD2.7) | 0.62 |
Median PreICU stay (range) | 0 (0–25) | 1 (0–32) | 0.21 |
Mean propensity scores (SD) | 0.58 (SD0.24) | 0.58 (SD0.24) | 0.99 |